StockNews.com Initiates Coverage on NovaBay Pharmaceuticals (NYSE:NBY)

Equities researchers at StockNews.com began coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a research note issued to investors on Thursday. The firm set a “hold” rating on the stock.

Separately, Ascendiant Capital Markets lowered their target price on NovaBay Pharmaceuticals from $8.00 to $0.85 and set a “buy” rating on the stock in a research note on Monday, November 11th.

NovaBay Pharmaceuticals Stock Down 1.3 %

Shares of NYSE:NBY opened at $0.66 on Thursday. NovaBay Pharmaceuticals has a 12-month low of $0.36 and a 12-month high of $9.08. The firm has a market capitalization of $3.23 million, a P/E ratio of -0.01 and a beta of 0.67. The firm has a fifty day moving average of $0.64 and a two-hundred day moving average of $0.61.

NovaBay Pharmaceuticals Company Profile

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.